Biological
Lenvervimab clinical trials
Also written GC1102.
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
5 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2015 | 2 |
| 2018 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses lenvervimab is read from its arms, and is right about nine times in ten.
Testing it · 5
- HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102Status unknownPhase 2/3Green Cross CorporationNCT03519113Written as GC1102 80,000 IU
- A Study of GC1102(Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B PatientsStatus unknownPhase 2Green Cross CorporationNCT03801798Written as GC1102
- A Phase 1 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B PatientsCompletedPhase 1Green Cross CorporationNCT02569372Written as GC1102
- A Phase 2 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in HBV-related Liver Transplant RecipientsCompletedPhase 2Green Cross CorporationNCT02304315Written as GC1102 50,000 IU
- Safety and Pharmacokinetics Study of Healthy Male Adults When Repeatedly Administered Through Intravenous InjectionCompletedPhase 1Green Cross CorporationNCT01606163Written as GC1102
Codes
What other systems call lenvervimab · ClinicalTrials.gg INT016605
- UNII (FDA) FX9X4L2A2LLENVERVIMABOne source FDA
- NCI Thesaurus C170106LenvervimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | FX9X4L2A2L | LENVERVIMAB | One source FDA |
| NCI Thesaurus | C170106 | Lenvervimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.